Faulty RNA Splicing of SCARB1 Linked to Metabolic Collapse in Early Pregnancy Loss

Anembryonic pregnancy, a form of early miscarriage in which a gestational sac develops but an embryo never forms, accounts for a notable share of all first-trimester pregnancy losses, yet its underlying biology remains frustratingly opaque. Now a team of researchers based in Beijing has traced a surprising thread through the molecular machinery of the condition: a failure in alternative splicing, the cellular process by which a single gene can produce multiple distinct proteins, appears to scramble amino acid metabolism in affected pregnancies. The study, published in Reproductive Sciences, points to the gene SCARB1, best known as a receptor for cholesterol transport, as a central player in this metabolic disruption, offering one of the most detailed molecular portraits of anembryonic pregnancy assembled to date.

The researchers, led by Qingyu Zhang and Xiaolin Lu of the Capital Institute of Pediatrics together with colleagues at Capital Medical University, the Chinese People’s Liberation Army General Hospital Eastern Medical Branch, and Beijing University of Technology, combined metabolomics with transcriptome-wide sequencing to interrogate both sides of the puzzle at once. On the metabolic side, they used mass spectrometry to measure concentrations of amino acids and related metabolites in the serum of women with anembryonic pregnancy and compared those profiles against healthy pregnant controls. On the genomic side, they sequenced RNA from chorionic villi, the placental precursor tissue obtained from the affected pregnancies, and used a computational tool called rMATS to systematically catalog differences in alternative splicing between patients and controls.

Alternative splicing is the cell’s strategy for squeezing remarkable diversity out of a finite genome. After a gene is transcribed into precursor messenger RNA, segments called exons can be stitched together in different combinations while others are skipped, producing protein variants with distinct functions. The process is a fundamental driver of development and tissue identity, and errors in splicing have been implicated in conditions ranging from neurodegenerative disease to cancer. Previous work had already hinted that splicing matters in reproduction: animal studies have shown that splicing regulators shape placental growth, and disruptions of splicing factors have been linked to impaired placental development and spontaneous abortion in experimental models. What remained unknown was whether splicing defects contribute to the metabolic disturbances characteristic of anembryonic pregnancy specifically.

The scale of the splicing disruption the team documented was striking. Compared with healthy controls, patients with anembryonic pregnancy carried 903 genes showing differential alternative splicing and 558 differentially expressed genes. Among the splicing changes, exon skipping emerged as the predominant event type, meaning that in the affected tissue, specific exon segments were disproportionately excluded from the mature messenger RNA. Mass spectrometry independently confirmed that amino acid metabolism was indeed dysregulated in the patients’ serum, consistent with earlier metabolomic studies of early pregnancy loss and reinforcing the idea that the metabolic environment of the pregnancy goes awry when embryonic development fails.

Three genes stood out from the splicing analysis with the most significant alterations: PRKCD, which encodes a protein kinase involved in cell signaling and apoptosis; SCARB1, the scavenger receptor class B member 1 that serves as the major cell-surface receptor for high-density lipoprotein cholesterol; and METTL2B, a member of the methyltransferase family. In all three, the affected samples showed preferential exon inclusion rather than skipping, a shift that would change the protein products these genes yield in the chorionic villi. The team validated these findings using splicing-specific polymerase chain reaction, a technique that amplifies and distinguishes the exon-included and exon-excluded transcript forms, confirming that the sequencing results reflected genuine biological differences rather than computational artifacts.

The choice of SCARB1 as a headline finding carries considerable biological weight. The receptor it encodes, often called SR-BI, was identified in landmark work in the 1990s as the high-density lipoprotein receptor, and it plays a well-established role in cholesterol homeostasis. Intriguingly, prior research in mice had already shown that the splicing regulator RBFOX2 in the liver controls cholesterol levels by modulating Scarb1 alternative splicing, and independent studies have tied SR-BI to metabolic phenotypes in other contexts. The new study extends that logic to human early pregnancy, suggesting that when SCARB1 splicing goes wrong in chorionic villi, the consequences ripple outward into both lipid and amino acid metabolism.

To understand what might be driving the splicing changes, the investigators turned to motif analysis, a computational approach that searches DNA sequences near splicing events for binding signatures of transcription factors. The analysis predicted that SCARB1 is a potential target gene of TEAD4, a transcription factor with an established and critical role in early embryology. TEAD4 is a key effector of the Hippo signaling pathway, and in mouse studies it is required for the specification of the trophectoderm, the cell lineage that gives rise to the placenta. Work in human preimplantation embryos has similarly shown that TEAD4 regulates trophectoderm differentiation upstream of the gene CDX2, and separate research has demonstrated that loss of TEAD4 function impairs postimplantation development and has been implicated in early human pregnancy loss.

Functional experiments in the new study revealed that both SCARB1 and TEAD4 participate in the regulation of metabolism, including amino acid and lipid metabolism, linking the transcriptional regulator, its predicted splicing-sensitive target, and the metabolic derangements measured in patient serum into a coherent mechanism. The authors further examined correlations between the degree of SCARB1 exon exclusion and the serum concentrations of nineteen amino acids and metabolites, integrating transcription factor prediction with publicly available datasets to build a picture of how splicing-mediated changes could feed into systemic metabolic disruption. Protein-protein interaction analysis of pregnancy-related TEAD4 targets undergoing exon-skipping events added another layer, highlighting placenta-expressed genes within this regulatory network.

The study’s implications cut in two directions. Scientifically, it elevates alternative splicing-mediated metabolic reprogramming from a suspected mechanism to a documented feature of anembryonic pregnancy, connecting a transcription factor central to trophectoderm specification, a cholesterol receptor with newly appreciated metabolic reach, and the amino acid disturbances measurable in maternal blood. Clinically, the findings suggest potential avenues that were previously invisible: if the splicing pattern of SCARB1 or the serum amino acid profile proves robust in larger cohorts, such molecular signatures could eventually inform earlier diagnosis of anembryonic pregnancy or point toward metabolic interventions, although the authors’ work remains at the mechanistic stage and no diagnostic or therapeutic application follows directly from these results.

Important caveats temper the enthusiasm. The validation experiments compared eight patients with eight controls, a sample size that underscores the need for replication in larger and more diverse populations before the SCARB1-TEAD4 axis can be considered a confirmed driver of anembryonic pregnancy rather than a strongly supported hypothesis. The study also documents correlation and predicted regulation rather than demonstrating, through direct perturbation experiments, that correcting SCARB1 splicing rescues metabolic function. The RNA sequencing datasets have been deposited in the National Genomics Data Center under accession PRJCA041061, allowing other researchers to interrogate the data independently, and the work received support from the Beijing Research Ward Excellence Program, the National Natural Science Fund of Beijing, and the National Natural Science Foundation of China. Even with these limitations, the study marks a meaningful step toward explaining why some pregnancies stall before the embryo ever develops, and it reframes early pregnancy loss as a disorder that can begin with a misstep in how RNA is cut and pasted.

Subject of Research: The role of SCARB1 alternative splicing in amino acid metabolism dysregulation in anembryonic pregnancy

Article Title: Dysregulation of SCARB1 Alternative Splicing Disturbs Amino Acid Metabolism in Anembryonic Pregnancy

Article References: Zhang, Q., Wu, X., Liu, X., Wei, J., Wang, L., Cao, J., & Lu, X. (2026). Dysregulation of SCARB1 Alternative Splicing Disturbs Amino Acid Metabolism in Anembryonic Pregnancy. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02179-4

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02179-4

Keywords: anembryonic pregnancy, alternative splicing, SCARB1, TEAD4, amino acid metabolism, chorionic villi, RNA sequencing, miscarriage, metabolomics, transcription factors, early pregnancy loss, reproductive biology